|
Medlab Update to Shareholders
|
7 June 2023 at 10:45am
|
|
Response to ASX Query
|
23 March 2023 at 4:10pm
|
|
Medlab Update to Shareholders
|
21 March 2023 at 11:00am
|
|
Final Director's Interest Notice
|
16 March 2023 at 8:45am
|
|
Initial Director's Interest Notice
|
16 March 2023 at 8:45am
|
|
Company Status and Board Composition Updates
|
16 March 2023 at 8:45am
|
|
Appointment of External Consultants to Medlab
|
6 March 2023 at 4:50pm
|
|
Suspension from Official Quotation
|
27 February 2023 at 11:55am
|
|
Trading Halt
|
23 February 2023 at 9:55am
|
|
Aust ODC Approves NanaDol Export for UK Use
|
7 February 2023 at 10:35am
|
|
Appendix 4C Administrative Clarification
|
1 February 2023 at 4:30pm
|
|
UK Home Office Grants UK Import Certificate for NanaBis
|
25 January 2023 at 11:10am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
20 January 2023 at 2:10pm
|
|
Medlab Announces Interim Readout of RWE Medcare Study
|
12 January 2023 at 9:15am
|
|
Medlab Files Registration Statement for Proposed US IPO
|
28 December 2022 at 8:55am
|
|
NASDAQ Progression - Medlab Clears SEC Comments
|
8 December 2022 at 12:20pm
|
|
First Tranche IP Royalty Payment from Pharmacare
|
1 December 2022 at 8:40am
|
|
Medlab receives UK Import Permission from MHRA for NanaBis
|
25 November 2022 at 9:25am
|
|
Jefferies HealthCare Conference NanoCelle Presentation
|
16 November 2022 at 5:30pm
|
|
NanoCelle Nasal RNA (Nucleid Acid) Program Update
|
10 November 2022 at 11:20am
|
|
Medlab Presents NanoCelle at Jefferies Conference London
|
9 November 2022 at 1:25pm
|
|
Notification of cessation of securities - MDC
|
1 November 2022 at 8:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 October 2022 at 9:25am
|
|
Grant of waiver of Listing Rule 14.7
|
21 October 2022 at 2:10pm
|
|
MDC 2022 AGM Voting Results
|
30 September 2022 at 2:00pm
|
|
Medlab AGM Presentation
|
30 September 2022 at 11:15am
|
|
Medlab Progresses Nasdaq Dual Listing
|
28 September 2022 at 11:30am
|
|
Medlab Received 2022 R&D Claim
|
26 September 2022 at 11:20am
|
|
NanaBis and NanoCBD Clinical Development Update
|
16 September 2022 at 10:55am
|
|
Final Director's Interest Notice
|
6 September 2022 at 12:05pm
|
|
MDC Director Resignation Announcement
|
31 August 2022 at 8:35am
|
|
Corporate Governance Statement 2022
|
30 August 2022 at 12:50pm
|
|
Appendix 4G
|
30 August 2022 at 12:50pm
|
|
Annual Report to shareholders
|
30 August 2022 at 12:40pm
|
|
Preliminary Final Report
|
30 August 2022 at 12:30pm
|
|
MDC Notice of Annual General Meeting/Proxy Form
|
29 August 2022 at 11:05am
|
|
Biotech Investors' Conference Presentation
|
17 August 2022 at 3:55pm
|
|
Depression European Patent Accepted, Proceeding to Grant
|
10 August 2022 at 10:40am
|
|
Initial Director's Interest Notice
|
8 August 2022 at 9:35am
|
|
Leading Healthcare Executive joins Medlab Board
|
8 August 2022 at 9:35am
|
|
Share Consolidation update & despatch of holding statements
|
5 August 2022 at 3:20pm
|
|
UNSW Medlab Laboratory Collaboration Additional Information
|
2 August 2022 at 10:25am
|
|
Medlab enters Laboratory Collaboration with UNSW, Sydney
|
1 August 2022 at 10:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 July 2022 at 9:40am
|
|
Results of MDC July 2022 EGM
|
28 July 2022 at 2:30pm
|
|
Change of Director's Interest Notice
|
13 July 2022 at 10:30am
|
|
Change of Director's Interest Notice
|
11 July 2022 at 10:05am
|
|
Consolidation/Split - MDC
|
30 June 2022 at 8:50am
|
|
EGM Notice of Meeting to Approve Dual Listing to Nasdaq
|
29 June 2022 at 5:55pm
|
|
Trading Halt
|
28 June 2022 at 11:20am
|
Medlab Clinical